Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

The future may be getting brighter in terms of reducing the threat of the human immunodeficiency virus (HIV), infectious disease experts told Newsweek. With new treatments and maybe even a vaccine ...

Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP ...

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that demonstrated a 96% reduction in infection risk. The prestigious journal ...